Cathye Shu

Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus

Ronald van Vollenhoven, Kenneth Kalunian, Thomas Dörner et al. · Annals of the Rheumatic Diseases · 2022 · 80 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +13

The first‐in‐human study of CNTO 7160, an anti‐interleukin‐33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis

Ivo Nnane, Bart Frederick, Zhenling Yao et al. · British Journal of Clinical Pharmacology · 2020 · 36 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: A phase I, open-label, dose-escalation clinical study

Daniel Burge, S. Bookbinder, Alan Kivitz et al. · Clinical Therapeutics · 2008 · 28 citations

Medicine, Pharmacokinetics, Pharmacology +16

Integrated Population Pharmacokinetics of Etanercept in Healthy Subjects and in Patients With Rheumatoid Arthritis Ankylosing Spondylitis

Simon Zhou, Cathye Shu, Joan Korth‐Bradley et al. · The Journal of Clinical Pharmacology · 2010 · 26 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

Pharmacokinetic-Pharmacodynamic Modeling of Apratastat: A Population-Based Approach

Cathye Shu, Honghui Zhou, Mehri Afsharvand et al. · The Journal of Clinical Pharmacology · 2010 · 14 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +11